Real-world AML study to track treatment outcomes over 10 years
NCT ID NCT04777916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 5,000 adults with acute myeloid leukemia (AML) in French hospitals to see how they are actually treated and how they fare over time. Researchers will collect data on treatments, survival, and disease progression for up to 10 years. The goal is to understand real-world care outside of clinical trials, which may help improve future treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal which AML treatments work best in everyday practice, helping doctors make more informed decisions.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP-GHU - Hôpital AVICENNE
RECRUITINGBobigny, France
-
C H U DE LIMOGES- Hopital Dupuytren
RECRUITINGLimoges, France
-
CHRU de Lille- Hopital C. HURIEZ
RECRUITINGLille, France
-
CHU Dijon- François Mitterrand
ACTIVE_NOT_RECRUITINGDijon, 21000, France
-
CHU La Conception
RECRUITINGMarseille, France
-
CHU Nice,Hopital Archet 1
RECRUITINGNice, France
-
CHU de la cote de Nacre
RECRUITINGCaen, France
-
Centre Antoine Lacassagne
RECRUITINGNice, France
-
Centre Henri Becquerel
RECRUITINGRouen, France
-
Centre Hopsitalier de l'Est Francilien - Site de Meaux
RECRUITINGMeaux, France
-
Centre Hospitalier Dr Schaffner
RECRUITINGLens, France
-
Centre Hospitalier Lyon Sud
RECRUITINGPierre-Bénite, France
-
Centre Hospitalier René Dubos
RECRUITINGPontoise, France
-
Centre Hospitalier Valenciennes
NOT_YET_RECRUITINGValenciennes, France
-
Centre Hospitalier Victor Dupouy
RECRUITINGArgenteuil, France
-
Centre Hospitalier de Dunkerque
RECRUITINGDunkirk, France
-
Centre Hospitalier de Roubaix
RECRUITINGRoubaix, France
-
Centre Hospitalier de St Quentin
RECRUITINGSaint-Quentin, France
-
Centre Hospitalier de Versailles André Mignot
RECRUITINGLe Chesnay, France
-
Centre hospitalier Sud Francilien
RECRUITINGCorbeil-Essonnes, France
-
Chu Amiens
RECRUITINGAmiens, France
-
GHICL-Hopital St Vincent de Paul
RECRUITINGLille, France
-
Hopital Pitié-Salpétrière APHP
RECRUITINGParis, France
-
Hôpital Henri Mondor AP-HP
RECRUITINGCréteil, France
-
Hôpital MILITAIRE PERCY
RECRUITINGClamart, France
-
Hôpital Necker - APHP
RECRUITINGParis, France
-
Hôpital SAINT ANTOINE-APHP
RECRUITINGParis, France
-
Hôpital Saint Louis- APHP
RECRUITINGParis, France
-
Institut Curie - Hôpital René HUGUENIN
NOT_YET_RECRUITINGSaint-Cloud, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant